Provided by Tiger Trade Technology Pte. Ltd.

Senti Biosciences, Inc.

0.9000
-0.0200-2.17%
Post-market: 0.90500.0050+0.56%17:34 EDT
Volume:39.46K
Turnover:35.69K
Market Cap:23.54M
PE:-0.31
High:0.9421
Open:0.9366
Low:0.8900
Close:0.9200
52wk High:5.10
52wk Low:0.7970
Shares:26.16M
Float Shares:9.58M
Volume Ratio:0.31
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8700
EPS(LYR):-12.0350
ROE:-394.62%
ROA:-67.77%
PB:2.90
PE(LYR):-0.07

Loading ...

Senti Biosciences to present SENTI-202 Phase 1 data at 11th Annual Innate Killer Conference

Reuters
·
Yesterday

Senti Biosciences Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
Mar 17

Senti Biosciences CEO Timothy Lu to Present at Leerink Partners Global Healthcare Conference

Reuters
·
Mar 03

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

Reuters
·
Feb 24

Senti Biosciences Joins Cell & Gene Live Virtual Event on Emerging Cell Therapy Technologies

Reuters
·
Feb 20

BRIEF-Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202

Reuters
·
Feb 11

Senti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML

Reuters
·
Feb 11

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of Senti-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R Aml)

THOMSON REUTERS
·
Feb 11

Senti Biosciences to Present Gene Circuit Platform at Healthcare Conference Taipei

Reuters
·
Feb 03

Press Release: Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

Dow Jones
·
Jan 14

Senti Biosciences CEO to Join Cell and Gene Therapy Panel at Biotech Showcase

Reuters
·
Jan 09

Senti Biosciences Grants Stock Options to New Employee

Reuters
·
Dec 19, 2025

Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating

MT Newswires Live
·
Dec 10, 2025

Senti Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Dec 10, 2025

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?

Benzinga_recent_news
·
Dec 10, 2025

Senti Biosciences (SNTI.US) Surges Over 7% at Open on Positive Phase 1 SENTI-202 Trial Data

Stock News
·
Dec 09, 2025

Senti Biosciences Reports Promising Clinical Results for SENTI-202 in AML Trial

Reuters
·
Dec 09, 2025

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Senti-202 in the Treatment of Adults With Relapsed or Refractory Acute Myeloid Leukemia

THOMSON REUTERS
·
Dec 09, 2025

Senti Biosciences Initiated at Outperform by Leerink Partners

Dow Jones
·
Nov 21, 2025

Buy Rating for Senti Biosciences: Innovative Gene Circuit Platform Shows Promise in AML Treatment

TIPRANKS
·
Nov 21, 2025